Hepatitis C News and Research

Latest Hepatitis C News and Research

New hybrid vehicle to improve delivery of DNA vaccines is under development

Described recently in the Proceedings of the National Academy of Sciences, the technology is a biomedical advancement that could help unleash the potential of DNA vaccines, which despite two decades of research, have yet to make a significant impact in the treatment of major illnesses.

26 Nov 2014

Study finds that starting ART treatment soon after HIV infection improves immune health

HIV-1-infected U.S. military members and beneficiaries treated with antiretroviral therapy (ART) soon after infection were half as likely to develop AIDS and were more likely to reconstitute their immune-fighting CD4+ T-cells to normal levels, researchers reported Nov. 24 in JAMA Internal Medicine.

25 Nov 2014

New cell therapy offers hope for patients with liver cirrhosis

Liver disease patients could be helped by a new cell therapy to treat the condition.

24 Nov 2014

New look at the workings of HIV, other viruses

UC Davis researchers are getting a new look at the workings of HIV and other viruses thanks to new techniques in electron microscopy developed on campus.

18 Nov 2014

New study documents health dangers of male sex trade in Mexico City

A new study documents the stark health dangers of the male sex trade in the streets, hotels, and discotheques of Mexico City. Lead author and health economist Omar Galárraga's point in making the grim assessment of the legal but perilous market is to find an incentive that might reduce the spread of HIV and other diseases in the nation's community of men who have sex with men.

16 Nov 2014

Bacterial protein flagellin can prevent and cure rotavirus infection

Activation of the innate immune system with the bacterial protein flagellin could prevent and cure rotavirus infection, which is among the most common causes of severe diarrhea, says a Georgia State University research team that described the method as a novel means to prevent and treat viral infection.

14 Nov 2014

Montefiore Medical Center receives $3.5M grant to advance treatment for hepatitis C

Montefiore Medical Center received a $3.5 million grant as part of the $10 million Health Care Innovation Award from the Center for Medicare & Medicaid Services to identify, diagnose and treat people with hepatitis C (HCV).

13 Nov 2014

New treatment regimen for hepatitis C in transplant patients produces promising results

A new treatment regimen for hepatitis C, the most common cause of liver cancer and transplantation, has produced results that will transform treatment protocols for transplant patients, according to research published online today in the New England Journal of Medicine.

12 Nov 2014

Study examines overall survival of patients with chronic HCV infection, cirrhosis

Patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who attained sustained virological response (SVR) had survival comparable with that of the general population, whereas patients who did not attain SVR had reduced survival, according to a study in the November 12 issue of JAMA.

12 Nov 2014

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection.

11 Nov 2014

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014.

10 Nov 2014

Johnson & Johnson completes acquisition of Alios BioPharma

Johnson & Johnson today announced the completion of the acquisition of Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.

8 Nov 2014

BIOVISION's 10th edition to focus on today’s health challenges

BIOVISION, the annual life sciences forum organized by the Foundation for the University of Lyon, today announces its 10thedition, which will take place on April 15 and 16, 2015 at the Musée des Confluences in Lyon, France.

6 Nov 2014

NCI supports further clinical development of next-generation HPV vaccine

The National Cancer Institute in the USA is supporting the new vaccine developed at the MedUni Vienna against the human papillomavirus (HPV) with at least US$ 3.5 million. This is a major success for the developers and means that the foundations can now be laid for the clinical trials needed for licensing as a vaccine.

30 Oct 2014

MinuteClinic enters into clinical collaboration agreement with Lifespan

MinuteClinic, the retail medical clinic of CVS Health, and Lifespan, Rhode Island's largest health system, which includes five partner hospitals and multiple physician groups, announced today that they have entered into a clinical collaboration agreement.

27 Oct 2014

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 (“miR-122”), for the treatment of hepatitis C virus infection (“HCV”).

22 Oct 2014

Few California inmates with hepatitis C get costly Sovaldi

In San Francisco's jails, no inmates with hepatitis C are receiving Sovaldi, the breakthrough pill that can cure most patients in an unprecedented amount of time.

21 Oct 2014

Newly developed agent filters out toxins from body in the event of overdose

Every minute counts in the event of an overdose. ETH professor Jean-Christophe Leroux and his team have developed an agent to filter out toxins from the body more quickly and efficiently.

17 Oct 2014

Foreign-born residents with low vaccination rates face greater risk of exposure to diseases

Foreign-born residents with low vaccination rates and their relatives in the U.S. are at greater risk of exposure to several vaccine-preventable diseases, e.g. influenza; pneumococcal diseases; tetanus, diphtheria and pertussis; hepatitis A; hepatitis B; shingles; and HPV, the human papilloma virus, which can lead to some types of cancer.

16 Oct 2014

State highlights: Supreme Court to hear N.C. scope-of-practice case; states weigh costs of new hepatitis C drugs

The Supreme Court on Tuesday will consider who can whiten teeth in North Carolina, a seemingly small decision that could have major implications for scope-of-practice throughout the country. In North Carolina Board of Dental Examiners v. Federal Trade Commission, the justices will weigh whether the state dental board's decisions -; in this case, a decision to not allow anyone but a dentist to whiten teeth -; are immune from antitrust protections typically granted to state agencies (Haberkorn, 10/13).

15 Oct 2014

Hepatitis C News and Research

Latest Hepatitis C News and Research

New hybrid vehicle to improve delivery of DNA vaccines is under development

Study finds that starting ART treatment soon after HIV infection improves immune health

New cell therapy offers hope for patients with liver cirrhosis

New look at the workings of HIV, other viruses

New study documents health dangers of male sex trade in Mexico City

Bacterial protein flagellin can prevent and cure rotavirus infection

Montefiore Medical Center receives $3.5M grant to advance treatment for hepatitis C

New treatment regimen for hepatitis C in transplant patients produces promising results

Study examines overall survival of patients with chronic HCV infection, cirrhosis

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Johnson & Johnson completes acquisition of Alios BioPharma

BIOVISION's 10th edition to focus on today’s health challenges

NCI supports further clinical development of next-generation HPV vaccine

MinuteClinic enters into clinical collaboration agreement with Lifespan

Regulus Therapeutics demonstrates human proof-of-concept with microRNA therapeutic

Few California inmates with hepatitis C get costly Sovaldi

Newly developed agent filters out toxins from body in the event of overdose

Foreign-born residents with low vaccination rates face greater risk of exposure to diseases

State highlights: Supreme Court to hear N.C. scope-of-practice case; states weigh costs of new hepatitis C drugs

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in